ECSP10010656A - Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1 - Google Patents

Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1

Info

Publication number
ECSP10010656A
ECSP10010656A EC2010010656A ECSP10010656A ECSP10010656A EC SP10010656 A ECSP10010656 A EC SP10010656A EC 2010010656 A EC2010010656 A EC 2010010656A EC SP10010656 A ECSP10010656 A EC SP10010656A EC SP10010656 A ECSP10010656 A EC SP10010656A
Authority
EC
Ecuador
Prior art keywords
nip
beta
inhibitors
hydroxiesteroid
deshidrogenasa
Prior art date
Application number
EC2010010656A
Other languages
English (en)
Inventor
Christine Charon
Denis Carniato
Didier Roche
Caroline Leriche
Liliane Doare
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010656A publication Critical patent/ECSP10010656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención se refiere a derivados de NIP tiazol de la fórmula (I) como inhibidores selectivos de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1 (11-?-HSD-1) y al uso de tales compuestos para el tratamiento y la prevención de síndrome metabólico, diabetes, resistencia a la insulina, obesidad, trastornos de los lípidos, glaucoma, osteoporosis, trastornos cognitivos, ansiedad, depresión, trastornos inmunes, hipertensión y otras enfermedades y condiciones patológicas.
EC2010010656A 2008-05-05 2010-12-02 Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1 ECSP10010656A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290424 2008-05-05

Publications (1)

Publication Number Publication Date
ECSP10010656A true ECSP10010656A (es) 2011-01-31

Family

ID=40935480

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010656A ECSP10010656A (es) 2008-05-05 2010-12-02 Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1

Country Status (18)

Country Link
US (1) US8546575B2 (es)
EP (1) EP2271405B1 (es)
JP (1) JP5735412B2 (es)
KR (1) KR101604366B1 (es)
CN (1) CN102015026B (es)
AR (1) AR072666A1 (es)
AU (1) AU2009243812B2 (es)
BR (1) BRPI0911497B8 (es)
CA (1) CA2723431C (es)
CO (1) CO6331305A2 (es)
EA (2) EA201300759A1 (es)
EC (1) ECSP10010656A (es)
ES (1) ES2432383T3 (es)
IL (1) IL208989A (es)
MX (1) MX2010011917A (es)
NZ (1) NZ589691A (es)
WO (1) WO2009135581A2 (es)
ZA (1) ZA201008723B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE518857T1 (de) * 2007-06-01 2011-08-15 Hoffmann La Roche Piperidin-amidderivate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015005305A1 (ja) 2013-07-09 2015-01-15 小野薬品工業株式会社 Ａｌｘｒ作動化合物
CN104910083A (zh) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 烷氧苯基三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途
CN104910084A (zh) * 2015-07-13 2015-09-16 佛山市赛维斯医药科技有限公司 末端胺基取代的三氮唑亚砜类化合物、其制备方法及其用途
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
KR20200105652A (ko) * 2017-09-08 2020-09-08 피아이 인더스트리스 엘티디. 새로운 살균성 헤테로시클릭 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US20070231263A1 (en) * 2004-04-13 2007-10-04 Jun Qiu Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102006010923A1 (de) 2006-03-09 2007-09-13 Saltigo Gmbh Verfahren zur Herstellung von Chlor-1,4-dimethoxybenzol
BRPI0709595A2 (pt) * 2006-03-15 2011-07-19 4Sc Ag inibidores de nf-kapab heterocìclicos
EP1994017A2 (en) 2006-03-15 2008-11-26 4Sc Ag Novel heterocyclic nf-kb inhibitors

Also Published As

Publication number Publication date
ZA201008723B (en) 2012-01-25
US20110060007A1 (en) 2011-03-10
JP2011521907A (ja) 2011-07-28
EP2271405B1 (en) 2013-07-24
US8546575B2 (en) 2013-10-01
CN102015026B (zh) 2015-11-25
BRPI0911497B1 (pt) 2021-01-26
AU2009243812B2 (en) 2014-06-05
IL208989A0 (en) 2011-01-31
CN102015026A (zh) 2011-04-13
CA2723431A1 (en) 2009-11-12
CO6331305A2 (es) 2011-10-20
KR20110004468A (ko) 2011-01-13
AR072666A1 (es) 2010-09-15
AU2009243812A1 (en) 2009-11-12
WO2009135581A3 (en) 2010-08-19
IL208989A (en) 2014-01-30
WO2009135581A2 (en) 2009-11-12
KR101604366B1 (ko) 2016-03-17
JP5735412B2 (ja) 2015-06-17
EA201001737A1 (ru) 2011-06-30
WO2009135581A9 (en) 2010-11-11
MX2010011917A (es) 2010-11-26
EA018920B1 (ru) 2013-11-29
EP2271405A2 (en) 2011-01-12
EA201300759A1 (ru) 2013-11-29
NZ589691A (en) 2012-11-30
ES2432383T3 (es) 2013-12-03
CA2723431C (en) 2016-11-22
BRPI0911497A2 (pt) 2019-01-15
BRPI0911497B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ECSP10010656A (es) Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1
ECSP10010231A (es) Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
PT1960352E (pt) Derivados de 2-adamantilureia como inibidores seletivos de 11â-hsd1
CR10401A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BRPI0606228A2 (pt) inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
IL213425A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
ECSP088839A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
MX347145B (es) Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa.
SV2009003275A (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
CY1110928T1 (el) Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
ECSP088849A (es) Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CR20110255A (es) Nuevos compuestos 578
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
ECSP13012896A (es) Derivados heterocíclicos de amina
DK1827427T3 (da) Aryloxyethylaminderivater med en kombination af partiel dopamin-D2 receptoragonisme og inhibition af genoptag af serotonin
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
MY173696A (en) Cyclic amide derivatives as inhibitors of 11-beta- hydroxysteroid dehydrogenase and uses thereof
CO7200248A2 (es) Derivados de etinilo como moduladores de la actividad de los receptores mglur5
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
MY192815A (en) Derivatives of aza adamantanes and uses thereof
EA201100419A1 (ru) Сопряженные пирролидино-циклопропановые производные в качестве селективных ингибиторов 11-бета-гидроксистероид дегидрогеназы 1 типа
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
DOP2009000125A (es) Derivados de azacicloalcanos como inhibidores de esteraoil-coenzima a delta-9 desaturasa